Protein kinase CβⅡ promoting the development of hepatocellular  carcinoma via inducing epithelial-mesenchymal transition and angiogenesis

LIU Min ZENG Yun ZHU Shan-shan WU Jia-cui GAO Hong-quan YI Xue

Acta Anatomica Sinica ›› 2020, Vol. 51 ›› Issue (6) : 912-918.

PDF(7816 KB)
Welcome to visit Acta Anatomica Sinica! Today is Chinese
PDF(7816 KB)
Acta Anatomica Sinica ›› 2020, Vol. 51 ›› Issue (6) : 912-918. DOI: 10.16098/j.issn.0529-1356.2020.06.016
Cancer Biology

Protein kinase CβⅡ promoting the development of hepatocellular  carcinoma via inducing epithelial-mesenchymal transition and angiogenesis

  • LIU Min1, 2  ZENG Yun1,2  ZHU Shan-shan3  WU Jia-cui1  GAO Hong-quan1  YI Xue1,2*
Author information +
History +

Abstract

Objective  To explore the function and mechanism of protein kinase CβⅡ(PKCβⅡ) in the progression of hepatocellular carcinoma(HCC).   Methods  The expression of PKCβⅡ in hepatic cell L02 and HCC cell lines (SK-hep1, HepG2, BEL-7404, 7721, Hep3B and huh7)was examined by Western blotting. Stable HCC cells over-expressing PKCβⅡ were constructed, the morphological change was observed under inverted phase microscope, immunofluorescence was applied to examine the expression of E-cadherin and N-cadherin. Western blotting, Real-time PCR and cycloheximide (CHX) chase assay were used to examine the molecular mechanism of PKCβⅡ in modulating the expression of  E-cadherin, N-cadherin and Snail. The effect of PKCβⅡ on the metastasis of HCC was examined by using transwell assay and nude mice tail vein injection. Tube formation assay was used to detect the impact of PKCβⅡ on the tube formation by human umbilical vein endothelial cells(HUVECs), enzyme linked immunosorbent assay(ELISA) was used to detect the impact of PKCβⅡ on the content of vascular endothelical growth factor(VEGF)A in the supernatant of HCC cells.   Results  The expression of PKCβⅡ in HCC cells was higher than that in hepatic cell L02, PKCβⅡ promoted the morphologic phenotype changed from cobblestone-like epithelial cells to spindle-shaped mesenchymal-like cells, with the expression of E-cadherin down-regulated(P<0.05)and N-cadherin up-regulated(P<0.01) at mRNA level, as well as Snail up-regulated at translation level. Meanwhile, PKCβⅡ improved migratory and invasive abilities(P<0.01)of HCC cells as well as VEGFA secretion(P<0.01)and angiogenesis(P<0.01).   Conclusion  Protein kinase CβⅡ promotes the development of hepatocellular carcinoma via inducing epithelial-mesenchymal transition and angiogenesis.

Key words

Protein kinase CβⅡ / Hepatocellular carcinoma / Epithelial-mesenchymal transition / Angiogenesis / Western blotting / Nude mouse

Cite this article

Download Citations
LIU Min ZENG Yun ZHU Shan-shan WU Jia-cui GAO Hong-quan YI Xue. Protein kinase CβⅡ promoting the development of hepatocellular  carcinoma via inducing epithelial-mesenchymal transition and angiogenesis[J]. Acta Anatomica Sinica. 2020, 51(6): 912-918 https://doi.org/10.16098/j.issn.0529-1356.2020.06.016

References

[1] Bray F, Ferlay J, Soerjomataram Ⅰ, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression[J]. Semin Cancer Biol, 2018, 48(2):36-52.
[3] Al-Sanabra O, Duckworth AD, Glenn MA, et al. Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CbetaII in chronic lymphocytic leukaemia cells[J]. Sci Rep, 2017, 24(7):43228-43240.
[4] Murray NR, Weems J, Braun U, et al. Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression[J]. Cancer Res, 2009, 69(2):656-662.
[5] G?kmen-Polar Y, Mehta R, Tuzmen S, et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes[J]. Breast Cancer Res Treat, 2010, 124(2):327-335.
[6] Chu PY, Hsu NC, Lin SH, et al. High nuclear protein kinase CβⅡ expression is a marker of disease recurrence in oral squamous cell carcinoma[J]. Anticancer Res, 2012, 32(9):3987-3991.
[7] El Osta M, Liu M, Adada M, et al. Sustained PKCβⅡ activity confers oncogenic properties in a phospholipase D-and mTOR-dependent manner [J]. FASEB J, 2014, 28(1):495-505.
[8] He LF, Wang TT, Gao QY, et al. Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells[J]. J Biomed Sci, 2011, 18(1):39-47.
[9] Duan F, Wu H, Jia D, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis[J]. J Hepatol, 2018, 68(6):1191-1202.
[10] Ruan Y, Sun L, Hao Y, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma[J]. J Clin Invest, 2012, 122(7):2554-2566.
[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[12] Zheng JX, Zhu Q, Liu Ch, et al. Expression of interleukin-34/colony stimulating factor-1R in the process of transforming growth factor-β1 inducing A549 cells transition[J]. Acta Anatomica Sinica, 2014,45(3):393-397.(in Chinese)
郑金旭,朱勤,刘超,等. 白细胞介素-34/集落刺激因子-1R在转化生长因子-β1诱导A549细胞上皮-间质转化中的表达[J]. 解剖学报,2014, 45(3):393-397.
[13] Gui Y, Khan MGM, Bobbala D, et al. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1[J]. World J Gastroenterol, 2017, 23(36):6639-6649.
[14] Kim DH, Xing T, Yang Z, et al. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview[J]. J Clin Med, 2017, 7(1):1-25.
[15] Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma[J]. Hepatology, 2009, 50(5):1464-1474.
[16] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2):69-84.
[17] Hu S, Liu Y, You T, et al. Semaphorin 7A promotes VEGFA/VEGFR2-mediated angiogenesis and intraplaque neovascularization in ApoE(-/-) Mice[J]. Front Physiol, 2018, 30(9):1718-1730.
[18] Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma[J]. Front Pharmacol, 2016, 9(7):428-438.
[19] Gadaleta-Caldarola G, Divella R, Mazzocca A, et al. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond[J]. Future Oncol, 2015, 11(16):2263-2266.
[20] Chen J, Jin R, Zhao J,et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma[J]. Cancer Lett, 2015, 367(1):1-11.
[21] Dong J, Zhai B, Sun W, et al. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells[J]. PLoS One, 2017, 12(9):e0185088.
PDF(7816 KB)

Accesses

Citation

Detail

Sections
Recommended

/